Vigil Neuroscience — Technical Presentation (September 2023)
71 slides from Vigil Neuroscience's technical presentation, Sep 13, 2023
Slide 1: Vigil Neuroscience Small Molecule KOL Event
Exhibit 99.1 Vigil Neuroscience Small Molecule KOL Event September 13, 2023 © Vigil Neuroscience, Inc. 2023. All rights reserved.
Slide 2: Today's Agenda
Today’s Agenda 7:30 – 7:35 AM (5 min) 8:30 – 8:45 AM (15 min) Opening Remarks & Corporate Overview Alzheimer’s Disease Treatment & Unmet Need Ivana Magovčević-Liebisch, PhD, JD Samuel E. Gandy, PhD, MD Chief Executive Officer, Vigil Neuroscience, Inc. Mount Sinai Professor of Alzheimer’s Disease Res
Slide 3: Reminders
Reminders § Webcast scheduled to end at 9:00am U.S. ET § Presentation is available in investors section under Events & Presentations at www.vigilneuro.com § Moderated Q&A session following prepared remarks § To submit a written question, fill out form on webcast home page § Webcast replay available
Slide 4: Forward-Looking Statements
Forward-Looking Statements This presentation contains “forward-looking statements,” which are made pursuant to the safe harbor provisions of the federal securities laws, including the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact may be d
Slide 5: Corporate Overview
Corporate Overview Ivana Magovčević-Liebisch, PhD, JD Chief Executive Officer Vigil Neuroscience, Inc. © Vigil Neuroscience, Inc. 2023. All rights reserved.
Slide 6: Vigil Neuroscience
Vigil Neuroscience Vigil Neuroscience is a clinical-stage microglia- focused therapeutics company § Founded ~3 years ago in July 2020 § Our purpose: to treat rare and common neurodegenerative diseases by restoring the vigilance of microglia, the brain’s sentinel immune cells § Precision-based strate
Slide 7: Vigil's Precision Medicine Strategy to Target Broad Range of Neurodegenerative Diseases
Vigil’s Precision Medicine Strategy to Target Broad Range of Neurodegenerative Diseases Pipeline Candidates for Genetically Defined Subpopulations in First Indication Common Indications Rare (AD) Microgliopathy Further Expansion (ALSP) into Broader Populations in Data Driven Common Indications Expan
Slide 8: Vigil TREM2 Agonists: Differentiated Strategy & Multiple Modalities
Vigil TREM2 Agonists: Differentiated Strategy & Multiple Modalities Vigil Neuroscience Small Molecule TREM2 mAb in TREM2 Agonist in Development for Development for ALSP: VGL101 AD: VG-3927 st The 1 & ONLY TREM2 small The ONLY targeted drug candidate molecule agonist entering clinical in development
Slide 9: VG-3927: Small Molecule TREM2 Agonist Well-Positioned for AD
VG-3927: Small Molecule TREM2 Agonist Well-Positioned for AD § First & only small molecule TREM2 agonist entering clinical development § Excellent profile as potential treatment for Alzheimer’s Disease (AD): – Oral dosing – Superior brain penetration & differentiated pharmacokinetics & MoA vs antibo
Slide 10: Featured Key Opinion Leaders (KOLs)
Featured Key Opinion Leaders (KOLs) Marco Colonna, MD Robert Rock Belliveau Professor of Pathology & Immunology Washington University School of Medicine, St. Louis, MO Vigil Neuroscience, Inc. Scientific Advisory Board Chairman Samuel E. Gandy, MD, PhD Mount Sinai Professor of Alzheimer’s Disease Re
Slide 11: TREM2 Concept in Alzheimer's Disease (AD)
TREM2 Concept in Alzheimer’s Disease (AD) Marco Colonna, MD Robert Rock Belliveau Professor of Pathology & Immunology Washington University School of Medicine, St. Louis, MO Vigil Neuroscience, Inc. Scientific Advisory Board Chairman
Slide 12: Unique Developmental Origin of the Brain Resident Immune System
Unique Developmental Origin of the Brain Resident Immune System Microglial-specific Markers: CD11b low CD45 high Cx3cr1 Tmem119 FCRLS P2RY12 Sall1 https://www.mdpi.com/1422-0067/22/18/9706 12
Slide 13: Microglia in Healthy & Disease States
Microglia in Healthy & Disease States Microglia are Brain-resident First Microglia are Key to Maintaining Normal Brain Responders to Acute Brain Injury Homeostasis and Neuronal Function Microglia surveillance of healthy brain to maintain Microglia processes quickly and precisely orient to Microglia
Slide 14: Microglia Migration into AD's Neuropathological Amyloid Plaque Microenvironment
Microglia Migration into AD's Neuropathological Amyloid Plaque Microenvironment Healthy Control Brain Alzheimer’s Disease Brain Amyloid plaque Microglia Microglia Insoluble ApoE Microglia marker Amyloid plaque Aggregated ApoE Colonna Lab, unpublished data 14
Slide 15: Genetics of AD Inspire the Next Generation of Microglia-Targeted Therapeutics
Genetics of AD Inspire the Next Generation of Microglia-Targeted Therapeutics Expansion of AD Sequenced Genomes Identifies AD Genetics-identified Genes Rare And Novel Causal Genetic Risk Factors Enriched in Microglia Astrocytes Oligos ABCA7 PTK2B RIN3 SORL1 SPI1 ZCWPW1 CR1 NME8 BIN1 CD33 MS4A6A IL1R
Slide 16: Targeting Neuroimmunology Specifically for Alzheimer's Disease
Targeting Neuroimmunology Specifically for Alzheimer’s Disease Distinct Genetic Links vs Inflammation Disease States Human Genetic Underpinnings of Alzheimer’s Disease Biological Substrates of Multiple Point Directly to TREM2 with Further Validation by Sclerosis Points to a Distinct Multiple Pathway
Slide 17: Why All the Focus on TREM2?
Why All the Focus on TREM2? Overwhelming Human Data Point to AD-risk Associated Gene, Protein & Cellular Dysfunction Association of TREM2 Variants TREM2 Mutations in AD Gene Expression in Sporadic AD with AD Risk is Robust and Suggest Loss of Ligand Binding Further Validates Involvement of Highly Re
Slide 18: Microglial Loss-of-Signaling Hypothesis for TREM2
Microglial Loss-of-Signaling Hypothesis for TREM2 TREM2-DAP12 Pathway & Its Importance Beyond AD TREM2-DAP12 Signaling Transduction and TREM2 and DAP12 Mutations Cause Rare Early-onset Familial Cellular Function in Microglia Microgliopathy Called Nasu-Hakola Disease (NHD) Low avidity ligand state Hi
Slide 19: TREM2's Role in Microglial Activation
TREM2's Role in Microglial Activation Disease State Molecular Evidence AD Mouse Models Human AD Validation TREM2 promotes non-inflammatory, TREM2 is required for neuroprotection within Plaque-associated microglia protect neuroprotective microglia state the amyloid plaque niche neighboring neurons Ke
Slide 20: Preclinical Proof-of-Principle via TREM2 Agonist Antibodies
Preclinical Proof-of-Principle via TREM2 Agonist Antibodies Target Validation via Pharmacological Modulation TREM2 Agonist Antibody Reduces Neuronal Damage Enhanced Brain Penetration Leads to Increased Locally Around Aβ Plaques Amyloid Reduction Control tvAb TREM2 tvAb TREM2/TfR bsAb Control TREM2 A
Slide 21: Leveraging Microglia to Restore Tissue Homeostasis in AD
Leveraging Microglia to Restore Tissue Homeostasis in AD Evidence from Recent Anti-Aβ Therapeutics Antibody full effector function drives microglial Aβ Anti-Aβ dual binding to AD substrate and microglia clearance Microglia Recruitment Microglia and Aβ Clearance AD Pathological Forms of Aβ Effector i
Slide 22: Breakthroughs in Neuroimmunology Seed a Promising New Outlook for AD Therapeutics
Breakthroughs in Neuroimmunology Seed a Promising New Outlook for AD Therapeutics Summary of Key Concepts § Genetics of AD point to microglia as the next generation therapeutics § TREM2 is both directly implicated as a causal gene as well as indirectly as a genetic hub § Extensive research points to
Slide 23: Acknowledgements
Acknowledgements Washington Univ. Weizmann Institute University of Brescia Vigil Neuroscience Alector Marina Cella Ido Amit Luigi Poliani David Gray Tina Schwabe Susan Gilfillan Hadas Keren-Shaul William Vermi Christian Mirescu Meer Moustafa Mattia Bugatti Borislav Dejanovic Ilaria Tassi Jonathan Ki
Slide 24: VG-3927: First & Only Small Molecule TREM2 Agonist Entering Clinical Development for Alzheimer's Disease
VG-3927: First & Only Small Molecule TREM2 Agonist Entering Clinical Development for Alzheimer’s Disease David Gray, PhD Chief Science Officer, Vigil Neuroscience, Inc. © Vigil Neuroscience, Inc. 2023. All rights reserved.
Slide 25: VG-3927: First & Only Clinical Oral Small Molecule TREM2 Agonist
VG-3927: First & Only Clinical Oral Small Molecule TREM2 Agonist We Are Microglia Experts O Ou ut ts st ta an nd di in ng g & & P Po ot te en nt t T TR RE EM M2 2 a ag go on ni is sm m B Br ro oa ad d a an nd d f fa av vo or ra ab bl le e d di if ff fe er re en nt ti ia at te ed d c cl li in ni ic c
Slide 26: VG-3927 Selected from High Quality Chemical Matter
VG-3927 Selected from High Quality Chemical Matter Deep Understanding of MoA with Multiple Excellent Back-up Compounds Highly Efficient and Structurally Diverse Target Coverage in CNS via Oral Dosing Strong Development Path § Consistent PK across preclinical species § CNS drug properties fully optim
Slide 27: VG-3927: Entering Phase 1 with Excellent Product Profile
VG-3927: Entering Phase 1 with Excellent Product Profile § TREM2 EC : < 0.003 µM 50 § TREM1 selectivity: > 50,000-fold § Clean profile (evaluated in ~350 § PK consistent with QD dosing Highly Potent & off-target assays) § CSF exposure ≈ free plasma Selective for TREM2 § No CYP inhibition liability §
Slide 28: Establishing VG-3927 for Development in AD
Establishing VG-3927 for Development in AD Pharmacological & Clinical Translation VG-3927 Pharmacological Profile VG-3927 Functional & Model System Profile TREM2 Human iPSC Human CNS Mouse Nonhuman engineered microglia tri-culture neurodegenerative primate profiling systems monocultures platform dis
Slide 29: VG-3927: Potent & Selective TREM2 Agonist
VG-3927: Potent & Selective TREM2 Agonist VG-3927 – Highly Selective Agonist for VG-3927 Signaling in Human Microglia is Fully TREM2 Over TREM1 Dependent on TREM2 125 DMSO Control 300 100 VG-3927 TREM2 EC <1nM 50 75 200 50 TREM1 EC >50,000 nM 50 100 25 0 0 TREM2 Wild-type TREM2 Knockout Microglia Mi
Slide 30: VG-3927: Potent TREM2 Agonist in Disease-Associated TREM2 Variants
VG-3927: Potent TREM2 Agonist in Neurodegenerative Disease- Associated TREM2 Variants Supports Precision-based Clinical Development Vigil Precision AD Strategy VG-3927 Potency Across Notable AD-risk Variants of TREM2 TREM2 R47H TREM2 R62H TREM2 H157Y TREM2 Highly Variant Potent 125 Common 100 Varian
Slide 31: VG-3927 Potentiates Signaling of Damage-associated Ligands
VG-3927 Potentiates Signaling of Damage-associated Ligands Damage-associated Ligand: Sulfatide Potentiation of TREM2 Focusing Efficacy in Pathological TREM2 Signaling Activation Activation Microenvironments VG-3927 800 High 600 VG-3927 Low VG-3927 400 + Sulfatide Plaque- 200 burdened CTL 100 AD Stat
Slide 32: TREM2 AD-risk Variants Are Loss of Function & Impact Signaling
TREM2 AD-risk Variants Are Loss of Function & Impact Signaling Example: R47H Leads to Defective Sensing of Sulfatide Mutation Impact: R47H TREM2 § Missense in ligand binding domain Variant § Loss of TREM2 response to sulfatide (damage-associated ligand) Damage- TREM2 Activation (CV vs R47H Variants)
Slide 33: VG-3927 Restores TREM2 Response to Damage-associated Ligand in R47H
VG-3927 Restores TREM2 Response to Damage-associated Ligand in R47H Rescues Signaling Impairment in AD-risk Variant § TREM2-R47H defective response to damage-associated ligand (sulfatide) VG-3927 § VG-3927 rescues signaling and response to sulfatide TREM2 SM for AD § Similar effects observed in TREM
Slide 34: VG-3927 Acts as a Molecular Glue to Stabilize TREM2 Complex
VG-3927 Acts as a Molecular Glue to Stabilize TREM2 Complex Novel Mechanism of Action Higher molecular weight band reveals novel receptor ligand complex Non-denatured states (Native PAGE) in iMGLs TREM2 immunoprecipitation in HEK system 34 Neg CTL: negative control; DMSO: dimethyl sulfoxide; KO: kno
Slide 35: VG-3927 Orchestrates Multi-Protein Interaction to Trigger Signaling
VG-3927 Orchestrates Multi-Protein Interaction to Trigger Signaling Unique Molecular Glue Mechanism of Action Unassembled Inactive VG-3927 Minimal TREM2 and DAP12 VG-3927 Brings Together Quantification of TREM2- TREM2 Receptor Complex TREM2 SM for AD Interaction at Baseline Both Signaling Partners D
Slide 36: Establishing VG-3927 for Development in AD
Establishing VG-3927 for Development in AD Pharmacological & Clinical Translation VG-3927 Pharmacological Profile VG-3927 Functional & Model System Profile TREM2 Human iPSC Human CNS Mouse Nonhuman engineered microglia tri-culture neurodegenerative primate profiling systems monocultures platform dis
Slide 37: VG-3927: First & Only Small Molecule TREM2 Agonist Entering Clinical Development for Alzheimer's Disease
VG-3927: First & Only Small Molecule TREM2 Agonist Entering Clinical Development for Alzheimer’s Disease Christian Mirescu, PhD Vice President, Head of Neuroimmunology, Vigil Neuroscience, Inc. © Vigil Neuroscience, Inc. 2023. All rights reserved.
Slide 38: Establishing VG-3927 for Development in AD
Establishing VG-3927 for Development in AD Pharmacological & Clinical Translation VG-3927 Pharmacological Profile VG-3927 Functional & Model System Profile TREM2 Human iPSC Human CNS Mouse Nonhuman engineered microglia tri-culture neurodegenerative primate profiling systems monocultures platform dis
Slide 39: Vigil Human CNS Platform Combines Neurons, Astrocytes & Microglia
Vigil Human CNS Platform Combines Neurons, Astrocytes & Microglia Human iMGL Monoculture Platform Human CNS Tri-culture Platform Pharmacology in disease-relevant human cells Bridge to a predictive human translational system § Microglial pharmacology§ Vigil’s fully human translational cell model § Ta
Slide 40: VG-3927 Functional Profiling in CNS Tri-Culture Platform
VG-3927 Functional Profiling in CNS Tri-Culture Platform VG-3927 Modulates Established VG-3927 Target Engagement Biomarker Platform Application: Understand 2,000 Mobilizing microglia response with a VG-3927 Downstream Biology & favorable, non-inflammatory profile Human Neuroprotective Actions 1,800
Slide 41: VG-3927: Enhances Signals of Microglia Mobilization
VG-3927: Enhances Signals of Microglia Mobilization Favorable, Non-inflammatory Profile Enhancement of Microglia Suppression of Migration Signal Pro-inflammatory Cytokines IL-1b Reduction IP-10 Increase VG-3927 Tunes Microglial Secreted Factors 4 0.25 * ** Chemotaxis * Signals 3 0.20 2 0.15 Baseline
Slide 42: VG-3927 Reduces Established Neurodegeneration Biomarkers
VG-3927 Reduces Established Neurodegeneration Biomarkers Reduction of Extracellular NfL & Tau VG-3927’s Impact on Key VG-3927 Reduces Extracellular NfL VG-3927 Reduces Extracellular Tau Neurodegeneration Biomarkers Accumulation in Human Tri-cultures Accumulation in Human Tri-cultures in Humans Vehic
Slide 43: VG-3927 Protects Against Inflammation-Induced Astrogliosis
VG-3927 Protects Against Inflammation-Induced Astrogliosis VG-3927 Reduces Astrogliosis TREM2 Agonism Activates Anti- GFAP: Marker of Astrogliosis Biomarker (GFAP) in Human CNS inflammatory Benefit Tri-cultures CTL VG-3927 Neurodeg Stimulus Extracellular GFAP LPS/IFNy Damage state 150 125 VG-3927 10
Slide 44: VG-3927 Protects Against Biomarkers of Inflammation-Induced Neurodegeneration
VG-3927 Protects Against Biomarkers of Inflammation-Induced Neurodegeneration TREM2 Agonism Activates Anti- VG-3927 Suppresses Extracellular NfL & Tau Accumulation in LPS Model inflammatory Benefit CTL VG-3927 CTL VG-3927 Neurodeg Stimulus LPS/IFNy 200 400 150 300 VG-3927 100 200 Neuro- inflammation
Slide 45: Establishing VG-3927 for Development in AD
Establishing VG-3927 for Development in AD Pharmacological & Clinical Translation VG-3927 Pharmacological Profile VG-3927 Functional and Model System Profile TREM2 Human iPSC Human CNS Mouse Nonhuman neurodegenerative engineered microglia tri-culture primate profiling disease models systems monocult
Slide 46: VG-3927: Functionally Active in AD State
VG-3927: Functionally Active in AD State VG-3927 & VGL101 mAb Activate Neuroprotective Genes Similarly Mouse Amyloidosis Model VG-3927 Recapitulates TREM2 VG-3927 Activates Protective VG-3927 Oral Dosing Antibody Gene Signatures Microglia Gene Signatures Amyloid-beta (Aβ) Microglia (Iba1) Model: 5xF
Slide 47: Exploring VG-3927 Therapeutic Effects in Aβ Plaque-bearing Mice
Exploring VG-3927 Therapeutic Effects in Aβ Plaque-bearing Mice Initial Pilot Study VG-3927 Effects in Humanized TREM2 Disease-modifying Effects of VG-3927 on Aβ Pathology & AD-related AD Mouse Model Hallmarks Intervention: Post-plaque deposition Vehicle VG-3927 vs Initial age: 4.5 month-old 5xFAD-h
Slide 48: VG-3927 Reduces Aβ Pathology in Plaque-bearing Mice
VG-3927 Reduces Aβ Pathology in Plaque-bearing Mice Preliminary Effects Following 6 Weeks of Oral Dosing VG-3927 Effects on VG-3927 Effects on VG-3927 Aβ Plaque Area Insoluble Aβ 1-42 Immunohistology from Brain Slices Biochemistry of Brain Homogenates § Trend toward reducing plaque 125 125 area and
Slide 49: VG-3927 Reduces Neuropathology-associated Aggregated ApoE
VG-3927 Reduces Neuropathology-associated Aggregated ApoE Preliminary Effects Following 6 Weeks of Oral Dosing Working Model of VG-3927 Modulation No Change in Soluble ApoE Reduced Aggregated ApoE Functional Form Pathological Form of AD-related Pathology Aβ-ApoE Complexes 125 125 100 100 VG-3927 Ext
Slide 50: Confirmation of Oral Bioavailability, Brain Penetrance & CNS Target Engagement
Confirmation of Oral Bioavailability, Brain Penetrance & CNS Target Engagement Favorable PK & PD Demonstrated in Non-Human Primates (NHPs) Translation Biomarker Path to Clinic CSF Biomarker of TREM2 Target Engagement VG-3927 CNS Exposures Reduction of sTREM2 in NHP CSF PK Following Single Oral Dose
Slide 51: Establishing VG-3927 for Development in AD
Establishing VG-3927 for Development in AD Pharmacological & Clinical Translation VG-3927 Pharmacological Profile VG-3927 Functional and Model System Profile TREM2 Human iPSC Human CNS Mouse Nonhuman engineered microglia tri-culture neurodegenerative primate profiling systems monocultures platform d
Slide 52: VG-3927: First & Only Clinical Small Molecule TREM2 Agonist for AD
VG-3927: First & Only Clinical Small Molecule TREM2 Agonist for AD Broad modulation of neuropathology by harnessing microglia VG-3927, TREM2 SM for AD § Phase 1 dosing in healthy volunteers to commence in Oct 2023 § Differentiated TREM2 agonist – Highly potent and selective – Orally bioavailable and
Slide 53: Alzheimer's Disease Treatment & Unmet Need
Alzheimer’s Disease Treatment & Unmet Need Samuel E. Gandy, PhD, MD Mount Sinai Professor of Alzheimer’s Disease Research, Professor of Neurology & Psychiatry Associate Director of Mount Sinai Alzheimer’s Disease Research Center, NYC Past Chairman, National Medical & Scientific Advisory Council of t
Slide 54: Alzheimer's Disease (AD)
Alzheimer’s Disease (AD) β-amyloid Tau § Progressive degenerative disease § Most common cause of dementia in elderly § Progressive memory loss, impaired thinking, disorientation, language problems, mood disturbances § Complete dependence in advanced stages Inflammation Neurodegeneration Multiple Pat
Slide 55: AD Presents a Significant Unmet Medical Need
AD Presents a Significant Unmet Medical Need 1 § An estimated 6.7 million Americans are living with Alzheimer’s disease – 1 in 9 people, age 65 and older has AD – Accounts for 60-80% of all dementia cases – Increasing incidence due to an aging population – 7th leading cause of death § Enormous socie
Slide 56: Current Treatment Options for AD
Current Treatment Options for AD Symptomatic Treatment Anti-Aβ Monoclonal Antibodies § Cholinesterase inhibitors and NMDA antagonists § Aβ lowering immunotherapies to improve symptoms § 22-30% slowing in clinical decline § Does not impact brain pathology or modify the § Administered by intravenous i
Slide 57: Anti-Aβ mAbs with Efficacy Are Associated with ARIA
Anti-Aβ mAbs with Efficacy Are Associated with ARIA § Transient radiographic finding, occurs early in the treatment course § Monitorable by MRI surveillance § Managed by dose titration and dose suspension Anti-Aβ mAbs Efficacy on CDR-SB Aβ plaque removal ARIA Effective at Lowering ~22-30% slowing ✓✓
Slide 58: Unmet Needs & Key Opportunities in AD Therapeutics
Unmet Needs & Key Opportunities in AD Therapeutics § ARIA a common side effect, § Efficacy limited to ~30% requires MRI monitoring slowing in clinical decline Greater Improved § Immunogenicity Efficacy Safety Combination Access § Intravenous infusions § Address broader biology of Therapy once/twice
Slide 59: Human Genetics Motivates Targeting Microglia for Next-gen AD Therapeutics
Human Genetics Motivates Targeting Microglia for Next-gen AD Therapeutics >30% of AD-risk Genes Are Expressed by Microglia APP AAP Metabolism Causes AD PSEN2 PSEN1 Tau Metabolism Cholesterol metabolism Rare alleles causing Immune Response Mendelian inheritance Endocytosis High Cytoskeleton Developme
Slide 60: Human Genetics & Disease Models Suggest Optimizing Microglia Function May Be Beneficial
Human Genetics & Disease Models Suggest Optimizing Microglia Function May Be Beneficial § AD-related TREM2 variants exhibit impaired ligand binding & partial loss-of- microglia function § Genetic mutations associated with reduced microglia function also implicated in other genetic forms of neurodege
Slide 61: TREM2-R47H Variant Carriers Exhibit Faster Decline & Worse Cognition
TREM2-R47H Variant Carriers Exhibit Faster Decline & Worse Cognition Compared to Non-Carriers Individuals with AD Cognitively Normal Elderly Carriers 20 Noncarriers Worsening 15 More impairment 1.67 CDR-SB/year 10 1.37 CDR-SB/year 5 23% faster decline in carriers p=0.02 0 2 4 6 8 10 Years Jonsson T
Slide 62: VG-3927: Well-Positioned for Clinical Development in AD
VG-3927: Well-Positioned for Clinical Development in AD § Orally bioavailable brain penetrant small molecule § Potent and highly TREM2-specific § Potentiates TREM2 response to natural damage ligands across different AD-associated genetic TREM2 variants § Optimal balance of promoting neuroprotective
Slide 63: VG-3927 Has Potential to Address Unmet Needs & Opportunities in AD
VG-3927 Has Potential to Address Unmet Needs & Opportunities in AD Mitigate ARIA Drive greater efficacy • No Fc-mediated interactions • Boosting microglial repair functions • Specificity of response to • Impact broader disease disease microenvironment pathophysiology Greater Improved • Favorable kin
Slide 64: Clinical Development of VG-3297, Vigil's Small Molecule TREM2 Agonist
Clinical Development of VG-3297, Vigil’s Small Molecule TREM2 Agonist David Gray, PhD Chief Science Officer Vigil Neuroscience, Inc. 64 © Vigil Neuroscience, Inc. 2023. All rights reserved.
Slide 65: VG-3927 Phase 1 Trial in Healthy Volunteers
VG-3927 Phase 1 Trial in Healthy Volunteers Trial Population§ Healthy volunteers (HVs) including an elderly cohort § Double-blind, placebo-controlled Trial Design § Single (SAD) & multiple (MAD) ascending dose cohorts § VG-3927 or placebo (oral dosing) Treatment Duration§ SAD – single dose § MAD – o
Slide 66: VG-3927: Early-stage Clinical Strategy to De-risk Development for AD
VG-3927: Early-stage Clinical Strategy to De-risk Development for AD § Safety, tolerability, PK & PD § SAD/MAD in healthy volunteers includes an elderly cohort in MAD Phase 1 § Target engagement: based on CSF levels of sTREM2; downstream PD: based on sCSF1R and osteopontin in CSF Healthy Volunteers
Slide 67: Closing Remarks
Closing Remarks Ivana Magovčević-Liebisch, PhD, JD Chief Executive Officer Vigil Neuroscience, Inc. © Vigil Neuroscience, Inc. 2023. All rights reserved.
Slide 68: VG-3927: Differentiated Oral TREM2 Agonist with De-risked Precision-based Clinical Strategy for AD
VG-3927: Differentiated Oral TREM2 Agonist with De-risked Precision-based Clinical Strategy for AD § First & only small molecule TREM2 agonist entering clinical development § Harnesses neuroprotective activity of microglia via highly-potent & specific TREM2 agonism § Differentiated profile to potent
Slide 69: VG-3927 Small Molecule TREM2 Agonist Milestones
VG-3927 Small Molecule TREM2 Agonist Milestones Q3 2023 Submit IND for VG-3927, oral small molecule TREM2 agonist ü Begin Phase 1 dosing of VG-3927 in healthy volunteers Oct 2023 Report interim Phase 1 SAD/MAD data of VG-3927 in healthy volunteers Mid-2024 69 © Vigil Neuroscience, Inc. 2023. All rig
Slide 70: Vigil is Well-positioned to Execute on Our Mission
Vigil is Well-positioned to Execute on Our Mission We are an experienced and Microglial biology is Our vision is a passionate team rapidly becoming a brighter tomorrow of innovators new frontier for for people with TREM2 deficiency CNS drug discovery devastating leads to microglial neurodegenerative
Slide 71: Q&A
Q&A 71 © Vigil Neuroscience, Inc. 2023. All rights reserved.
Vigil Neuroscience — Technical Presentation (September 2023) on 6ix